Table 1.
Published results of adoptive NK cell therapy for lymphoma
| Lymphoma type | NK Cell product | NK Cell source | NK cell dose | Lymphodepleting chemotherapy | Combination therapy | Outcomes | Author | Year |
|---|---|---|---|---|---|---|---|---|
| HL (n = 3), NHL (n = 8), Breast Cancer (n = 1) | Expanded | Autologous | 6.8 × 108–4 × 1010 NK Cells for 1 dose | None | IL-2 | Not Reported | Lister et al. [36] | 1995 |
| B cell NHL (n = 6) | Overnight IL-2 Activation | Haploidentical | 2 × 106–40 × 106/kg for 1 dose | Fludarabine, Cyclophosphamide | IL-2 + rituximab | 2 CR, 2 PR | Bachanova et al. [41] | 2010 |
| NHL (n = 6) HL (n = 2) MM (5) | Overnight IL-2 Activation | Haploidentical | 1 × 105–2 × 107/kg for 1 dose | None | Primary endpoint safety, 8/13 in remission | Klingemann et al. [40] | 2013 | |
| NHL (n = 2) and Advanced Solid Tumors (n = 18) | Expanded | Unrelated healthy donor | 1 × 106–3 × 107/kg for 1–3 doses | None | 8/17 SD | Yang et al. [42] | 2016 | |
| NHL (n = 15) | Overnight IL-2 Activation | Haploidentical | 0.5–3.27 × 107/kg for 1 dose | Fludarabine, Cyclophosphamide, Methylprednisolone | IL-2 + rituximab | 4/15 ORR, 2/15 CR | Bachanova et al. [21] | 2018 |
| NHL (n = 9) | Expanded | Autologous | 1 × 106–1 × 107/kg for 1 dose | none | rituximab | 7/9 with CR | Tanaka et al. [43] | 2020 |
NK natural killer, HL Hodgkin lymphoma, NHL non-Hodgkin lymphoma, IL-2 interleukin-2, CR complete response, PR partial response, MM multiple myeloma